Sales Methodologies
Which Sales Methodology Should You Use? SPIN vs MEDDIC vs Challenger vs BANT vs Sandler (2026)
Every sales leader Googles this question at least once. The honest answer most articles won't give you: there is no “best” methodology. The right one depends on your ACV, your sales cycle length, and how complex your buyer's decision-making committee actually is. A $15K transactional deal closed in two weeks should not be run through MEDDPICC. A $400K enterprise deal with seven stakeholders should not be run through BANT. And no methodology survives the forgetting curve — research shows reps lose roughly 75% of training content within six days without reinforcement, so the framework you pick is only as good as the practice volume behind it. Here's the comparison most articles won't give you, including where each framework actually breaks down in practice.
The 6 Sales Methodologies That Actually Matter in 2026
There are at least 30 named sales methodologies in circulation — Solution Selling, SNAP, Gap Selling, Value Selling, NEAT, FAINT, and on and on. The truth is that most of them are variations, rebrands, or partial overlaps of six core frameworks. If you understand these six, you understand roughly 90% of what every other methodology is doing under a different name:
SPIN (Situation, Problem, Implication, Need-payoff) is a discovery question framework. MEDDIC (Metrics, Economic Buyer, Decision Criteria, Decision Process, Identify Pain, Champion) is a qualification checklist. MEDDPICC adds Paper Process and Competition for enterprise procurement. Challenger is a selling style built on Teach, Tailor, Take Control. BANT (Budget, Authority, Need, Timeline) is the original lightweight qualification framework, still useful for high-volume SDR work. And Sandler is a permission-based selling system built on up-front contracts, a pain funnel, and the discipline to walk away from deals without budget or decision authority.
Notice that those six frameworks aren't even doing the same job. SPIN is about how you ask questions. MEDDIC and BANT are about what you need to confirm before you forecast. Challenger is about the posture you take in a meeting. Sandler is about the permission structure of the conversation. People argue about “SPIN vs Sandler” or “Sandler vs MEDDIC” like they're mutually exclusive — they're not. They sit on different layers of the call. The real choice is which combination of layers you install across your team, and in what order.
The Comparison Table
| Methodology | Best For | ACV Range | Sales Cycle | Strength | Weakness |
|---|---|---|---|---|---|
| SPIN | Complex consultative B2B | $10K–$1M+ | 1–12 months | Question rigor | Doesn't qualify |
| MEDDIC | Enterprise qualification | $25K–$500K | 2–6 months | Forecast accuracy | Not a sales process |
| MEDDPICC | Enterprise with formal procurement | $100K+ | 3–12 months | Catches late-stage killers | Heavyweight for SMB |
| Challenger | Disruptive enterprise | $50K–$1M+ | 3–9 months | Wins competitive deals | Hard to teach |
| BANT | Transactional / SDR | <$25K | 1–30 days | Fast qualify | Outdated questions |
| Sandler | Mid-market consultative | $25K–$500K | 1–6 months | Kills happy ears | Easy to do manipulatively |
When to Use Which — Decision Tree
Five common scenarios, and the methodology stack that actually fits each one:
- SMB / transactional sales: BANT for fast qualification, with a light SPIN layer to surface the implication of the problem. You don't have time for MEDDIC's full checklist when the deal closes in two weeks.
- Mid-market enterprise: SPIN for discovery (because you actually need to understand the buyer's world) plus MEDDIC for qualification (because you need to know if this deal is real before investing 60 days into it).
- Enterprise with procurement: MEDDPICC end-to-end. You cannot win a $300K deal without understanding the Paper Process and the Competition — they're the things that kill deals at the goal line.
- Disruptive new category: Challenger to reframe the buyer's thinking, plus MEDDIC to make sure the reframe actually translates into a closed deal and not just a great conversation.
- Renewal / expansion: SPIN-style questions to surface new pain, plus a custom NPS-style framework to track health. Most named methodologies were built for new logos, not the install base.
- Teams that chase happy-ear deals: Sandler. If your reps consistently forecast deals that die in late stage, the underlying disease is usually that they never qualified budget or decision properly. Sandler's up-front contracts and pain funnel are the most direct cure.
The Truth: Most Top Reps Use a Hybrid
If you watch the top 10% of reps at any growing B2B company, you'll notice they don't actually run a single methodology by the book. They use SPIN's question structure inside MEDDIC's qualification framework, and they bring Challenger tension into the conversation when the buyer's framing of the problem is wrong. The framework doesn't come up in their language — it's invisible scaffolding behind a fluent conversation.
A practical example: imagine a $250K mid-market deal. The top rep opens with SPIN-style situation and problem questions to map the buyer's actual world. Once pain is established, they pivot to MEDDIC — confirming the Economic Buyer is in the room, asking about the Decision Process, identifying a Champion. Mid-cycle, the buyer says “we're probably going to keep doing this in-house.” That's when Challenger shows up: the rep gently reframes why in-house has hidden costs the buyer isn't accounting for. Three methodologies, one call, no acronyms ever spoken out loud.
That's the right way to think about it. Methodologies aren't religions. They're tools you pull off the shelf when the situation calls for them. The mistake most sales orgs make is picking one methodology and forcing every rep to run every deal through it, regardless of fit. The result is reps who can recite the acronym but can't close. Train your reps in the underlying skill — discovery questioning, qualification rigor, commercial insight — and let them choose the framework that fits the deal in front of them.
What Each Methodology Gets Wrong
Every framework has a blind spot. The popular guides won't tell you these because they're busy selling certifications. Here's what each one actually misses:
- SPIN:Assumes you'll always have a long discovery. Some deals need to move faster, and SPIN's sequence can feel like a deposition when the buyer just wants a price.
- MEDDIC:It is not a sales process — just a qualification checklist. You still need a method for actually advancing the deal between calls.
- MEDDPICC:Heavyweight for sub-$50K deals. Running it on a transactional sale wastes both your time and the buyer's.
- Challenger:Hard to teach to junior reps; many fake the “tension” and end up sounding adversarial instead of insightful.
- BANT:The questions are outdated (modern buyers rarely have a fixed budget upfront), but the underlying framework of fit + readiness is still useful.
- Sandler:The techniques (reversals, negative reverse selling) can sound manipulative when used by reps who don't fully buy in. The methodology only works when it comes from genuine willingness to walk away.
NEAT Selling vs MEDDIC — The Comparison That Keeps Coming Up
NEAT Selling (Need, Economic impact, Access to authority, Timeline) was introduced by The Harris Consulting Group in 2014 as a deliberate alternative to BANT — same lightweight footprint, modernized for buyers who do not know their own budget yet. People compare it to MEDDIC because both replace BANT in enterprise contexts, but they are solving very different problems. NEAT is essentially a modernized BANT; MEDDIC is a much heavier qualification standard built for $100K+ deals with buying committees.
| Dimension | NEAT | MEDDIC |
|---|---|---|
| What it is | Lightweight qualification framework | Heavy enterprise qualification standard |
| Best ACV | $10K–$75K | $25K–$1M+ |
| Dimensions | 4 (Need, Economic impact, Access to authority, Timeline) | 6 (Metrics, Economic Buyer, Decision Criteria, Decision Process, Identify Pain, Champion) |
| Champion tracking | No | Yes — explicit dimension |
| Decision process map | Implicit (Access to authority) | Explicit — sequence and dates |
| Designed for | Replacing BANT in modern B2B | Enterprise SaaS with buying committees |
| Where it breaks | Too thin for procurement-heavy deals | Overkill for transactional SMB sales |
The honest take: NEAT is BANT done right, MEDDIC is a different category of tool. If you are an SDR qualifying inbound leads or an AE running $20K–$50K deals with a single decision-maker, NEAT is the better fit — it surfaces real economic impact without pretending you have a Champion you do not have. If you are an AE running enterprise software deals where there is a buying committee, procurement, a security review, and a real CFO sign-off, MEDDIC (or its extended cousin MEDDPICC) is the only framework with the dimensions to actually qualify those deals.
Many teams use both: NEAT for inbound lead qualification at the SDR layer, MEDDIC once a deal moves into the AE pipeline. They are not in competition. For deeper dives, see the dedicated MEDDIC guide and BANT guide — NEAT sits between the two on the complexity scale.
MEDDIC vs Challenger — Qualification Standard vs Selling Style
This is the comparison sales leaders argue about most, and it's built on a false premise. MEDDIC and Challenger aren't competing methodologies — they're not even the same kind of thing. MEDDIC is a qualification standard: it tells you whether a deal is real enough to forecast. Challenger is a selling style: it tells you how to run the conversation — lead with a commercial insight (Teach), make it specific to the buyer (Tailor), and drive the process (Take Control). One answers “is this deal real?” The other answers “how do I change how this buyer thinks?” Asking which is better is like asking whether a tape measure is better than a hammer.
| Dimension | MEDDIC | Challenger |
|---|---|---|
| What it is | Qualification standard | Selling style / posture |
| Question it answers | “Is this deal real enough to forecast?” | “How do I reframe how the buyer thinks?” |
| Layer of the deal | Behind the call — forecasting & deal review | Inside the call — live delivery |
| Best ACV | $25K–$1M+ | $50K–$1M+ |
| Core strength | Forecast accuracy; kills happy-ears deals | Wins competitive & “do nothing” deals via insight |
| Where it breaks | Not a sales process — won't tell you what to say | Hard to teach; juniors fake the tension and sound adversarial |
| Use them together? | Yes — Challenger to run the meeting, MEDDIC to qualify and forecast the deal behind it. | |
If someone genuinely forces a single choice, decide by your actual problem. If your reps forecast deals that die in late stage — great demos, friendly “champions,” no real economic buyer — your disease is qualification, and MEDDIC is the cure. If your reps lose to “we'll just keep doing this in-house” or get commoditized against three look-alike vendors, your disease is a lack of commercial insight, and Challenger is the cure. The two diseases are different, which is the whole reason the frameworks exist side by side.
In practice, the top 10% of enterprise reps run both at once: Challenger tension during the meeting to move the buyer off the status quo, and MEDDIC rigor behind the scenes so the reframed conversation actually converts into a forecastable deal instead of a great chat that goes nowhere. Teach the qualification standard first — it's easier to install and inspect — then layer Challenger once reps can run a clean MEDDIC deal in their sleep.
How to Choose Without Overthinking
Pick based on three things, in this order. First, ACV: anything under $25K runs on BANT, anything $25K–$100K runs on SPIN+MEDDIC, anything over $100K with formal procurement runs on MEDDPICC. Second, sales cycle: short cycles need lightweight frameworks, long cycles can absorb heavier ones. Third, team experience: if your reps are junior, start them on SPIN before layering MEDDIC. Challenger should be the last methodology you teach, not the first.
Roll out one methodology at a time. The biggest mistake we see is sales leaders who attend a conference, get excited, and try to install three frameworks in a quarter. Reps end up confused, managers end up inspecting against checklists nobody really understands, and the only thing that changes is the vocabulary on the deal review.
Train one methodology for 90 days minimum before you evaluate it. That's about how long it takes for the framework to stop feeling like a script and start feeling like a habit. If after 90 days of real reps and real coaching it's not improving win rates or forecast accuracy, then evaluate whether it's the wrong framework or wrong execution. Don't bail at week three.
One more honest note: the methodology you pick matters less than the consistency with which you inspect against it. A team running “just okay” MEDDIC with weekly deal reviews and disciplined Champion qualification will outperform a team running textbook Challenger with no reinforcement. Pick something defensible, then build the muscle around it. The framework is the easy part — the operating cadence is where most rollouts succeed or fail.
How AI Roleplay Helps Master Any Methodology
Methodology training fails for one reason almost every time: not enough practice reps. Reading the SPIN book or sitting through a MEDDIC certification is the easy part. Actually running the framework live, under pressure, with a real buyer pushing back — that's the part most reps never get enough of before they're thrown into pipeline. AI roleplay closes that gap.
- ✓ Run 10 SPIN discovery calls in a week, against different buyer types
- ✓ Practice MEDDIC qualification against a Champion, an Economic Buyer, and a hostile gatekeeper
- ✓ Try Challenger's Teach-Tailor-Take Control on a skeptic before you try it on a real prospect
- ✓ Drill Sandler up-front contracts and the pain funnel until they sound like sentences, not scripts
- ✓ Get scored on whether you actually hit the framework, not just whether you talked smoothly
The framework only sticks when it's been used. Reading about MEDDIC for the tenth time will not make you better at running MEDDIC calls. Running ten MEDDIC calls will.
Practice Any of These Methodologies
Pick a methodology, paste a LinkedIn URL, and run a live voice roleplay. SPIN, MEDDIC, Challenger, BANT, or Sandler — practice against the buyer you're actually meeting tomorrow.
Practice Any of These Methodologies →Frequently Asked Questions
What is the best sales methodology?
There is no single best sales methodology — the right one depends on your ACV, sales-cycle length, and how complex the buying committee is. As a rule of thumb: BANT or NEAT for sub-$25K transactional deals, SPIN plus MEDDIC for $25K–$100K mid-market deals, MEDDPICC for $100K+ enterprise deals with formal procurement, and Challenger layered on top when you need to reframe how the buyer thinks. Most top reps run a hybrid rather than one framework by the book.
MEDDIC vs Challenger — which is better?
It is a category mismatch: MEDDIC is a qualification standard (it tells you whether a deal is real enough to forecast) and Challenger is a selling style (it tells you how to run the conversation — Teach, Tailor, Take Control). They answer different questions, so they are not direct substitutes. If forced to choose one: use MEDDIC when your problem is forecast accuracy and slipped deals, and Challenger when your problem is losing to "do nothing" or being seen as an interchangeable vendor. Most strong enterprise reps use both — Challenger to run the meeting, MEDDIC to qualify the deal.
Can you use MEDDIC and Challenger together?
Yes, and most high-performing enterprise reps do. Challenger governs how you run the conversation — you lead with a commercial insight that reframes the buyer’s thinking, tailor it to their world, and take control of the process. MEDDIC governs what you confirm before you forecast — Metrics, Economic Buyer, Decision Criteria, Decision Process, Identify Pain, Champion. One is the delivery layer of the call; the other is the qualification layer behind it. They never conflict because they operate on different planes.
NEAT Selling vs MEDDIC — which should I use?
NEAT (Need, Economic impact, Access to authority, Timeline) is a lightweight qualification framework — essentially a modernized BANT — best for SDRs and AEs running $10K–$75K deals with a single decision-maker. MEDDIC is a heavier enterprise qualification standard built for $25K–$1M+ deals with buying committees, procurement, and a real economic buyer. Many teams use NEAT for inbound lead qualification at the SDR layer and switch to MEDDIC once a deal moves into the AE pipeline.
Is BANT outdated?
The BANT questions are dated — modern buyers rarely have a fixed budget defined upfront — but the underlying idea of confirming fit and readiness before investing in a deal is still sound. For high-volume SDR qualification, BANT (or its modern cousin NEAT) is fast and good enough. For enterprise deals with multiple stakeholders, BANT is too thin and you want MEDDIC or MEDDPICC instead.